These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27079840)

  • 1. Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis.
    Fitzpatrick JK; Downer EJ
    Neuropharmacology; 2017 Feb; 113(Pt B):618-626. PubMed ID: 27079840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor signalling as a cannabinoid target.
    Cui Sun M; Otálora-Alcaraz A; Prenderville JA; Downer EJ
    Biochem Pharmacol; 2024 Apr; 222():116082. PubMed ID: 38438052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delineating the Role of Toll-Like Receptors in the Neuro-inflammation Model EAE.
    Fallarino F; Gargaro M; Mondanell G; Downer EJ; Hossain MJ; Gran B
    Methods Mol Biol; 2016; 1390():383-411. PubMed ID: 26803641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why do cannabinoids not show consistent effects as analgetic drugs in multiple sclerosis?
    Lienau FS; Füllgraf H; Moser A; Feuerstein TJ
    Eur J Neurol; 2007 Oct; 14(10):1162-9. PubMed ID: 17880571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis.
    Downer EJ; Clifford E; Gran B; Nel HJ; Fallon PG; Moynagh PN
    J Biol Chem; 2011 Mar; 286(12):10316-28. PubMed ID: 21245146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Toll-like receptors: emerging therapeutics for multiple sclerosis management.
    Gambuzza M; Licata N; Palella E; Celi D; Foti Cuzzola V; Italiano D; Marino S; Bramanti P
    J Neuroimmunol; 2011 Oct; 239(1-2):1-12. PubMed ID: 21889214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of cannabinoids in multiple sclerosis.
    Teare L; Zajicek J
    Expert Opin Investig Drugs; 2005 Jul; 14(7):859-69. PubMed ID: 16022575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of Toll-like receptors in multiple sclerosis and possible targeting for therapeutic purposes.
    Gooshe M; Abdolghaffari AH; Gambuzza ME; Rezaei N
    Rev Neurosci; 2014; 25(5):713-39. PubMed ID: 24914714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cannabinoids in multiple sclerosis.
    Zajicek JP; Apostu VI
    CNS Drugs; 2011 Mar; 25(3):187-201. PubMed ID: 21323391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined cannabinoid therapy via an oromucosal spray.
    Perez J
    Drugs Today (Barc); 2006 Aug; 42(8):495-503. PubMed ID: 16969427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of IL-1R/TLR signalling in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Ruggiero V
    Curr Mol Med; 2012 Mar; 12(3):218-36. PubMed ID: 22082484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoids in multiple sclerosis: do they have a therapeutic role?
    Killestein J; Uitdehaag BM; Polman CH
    Drugs; 2004; 64(1):1-11. PubMed ID: 14723555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
    Moreno-Martet M; Feliú A; Espejo-Porras F; Mecha M; Carrillo-Salinas FJ; Fernández-Ruiz J; Guaza C; de Lago E
    Mult Scler Relat Disord; 2015 Nov; 4(6):505-11. PubMed ID: 26590655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CB receptor ligands from plants.
    Woelkart K; Salo-Ahen OM; Bauer R
    Curr Top Med Chem; 2008; 8(3):173-86. PubMed ID: 18289087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis.
    Khan H; Ghori FK; Ghani U; Javed A; Zahid S
    Mol Biol Rep; 2022 Jun; 49(6):5117-5131. PubMed ID: 35182322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoids and multiple sclerosis.
    Pertwee RG
    Pharmacol Ther; 2002 Aug; 95(2):165-74. PubMed ID: 12182963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards cannabis and cannabinoid treatment of multiple sclerosis.
    Croxford JL; Miller SD
    Drugs Today (Barc); 2004 Aug; 40(8):663-76. PubMed ID: 15510238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoids and multiple sclerosis.
    Pertwee RG
    Mol Neurobiol; 2007 Aug; 36(1):45-59. PubMed ID: 17952649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.